- Home
- SFST vs DMAC Comparison
SFST vs DMAC Comparison
Compare SFST & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFST
- DMAC
- Stock Information
- Founded
- SFST 1999
- DMAC 2000
- Country
- SFST United States
- DMAC United States
- Employees
- SFST N/A
- DMAC N/A
- Industry
- SFST Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SFST Finance
- DMAC Health Care
- Exchange
- SFST Nasdaq
- DMAC Nasdaq
- Market Cap
- SFST 335.4M
- DMAC 310.1M
- IPO Year
- SFST 1999
- DMAC N/A
- Fundamental
- Price
- SFST $44.48
- DMAC $7.01
- Analyst Decision
- SFST Buy
- DMAC Strong Buy
- Analyst Count
- SFST 1
- DMAC 3
- Target Price
- SFST $51.00
- DMAC $12.33
- AVG Volume (30 Days)
- SFST 18.7K
- DMAC 440.7K
- Earning Date
- SFST 10-21-2025
- DMAC 11-12-2025
- Dividend Yield
- SFST N/A
- DMAC N/A
- EPS Growth
- SFST 58.48
- DMAC N/A
- EPS
- SFST 2.69
- DMAC N/A
- Revenue
- SFST $102,878,000.00
- DMAC N/A
- Revenue This Year
- SFST $8.65
- DMAC N/A
- Revenue Next Year
- SFST $13.43
- DMAC N/A
- P/E Ratio
- SFST $16.62
- DMAC N/A
- Revenue Growth
- SFST 15.60
- DMAC N/A
- 52 Week Low
- SFST $29.14
- DMAC $3.19
- 52 Week High
- SFST $46.00
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- SFST 54.89
- DMAC 67.16
- Support Level
- SFST $44.13
- DMAC $6.83
- Resistance Level
- SFST $45.36
- DMAC $7.46
- Average True Range (ATR)
- SFST 0.88
- DMAC 0.42
- MACD
- SFST -0.14
- DMAC 0.08
- Stochastic Oscillator
- SFST 30.59
- DMAC 79.58
About SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.